The acquisitions of PetMedix (U.K.) and adivo GmbH (Germany) represent a strategic capital allocation to enhance R&D capabilities, specifically in antibody-based therapies. These deals create integration needs and signal a long-term investment focus on advanced biopharmaceuticals.
Filing excerpt
In 2023, the company completed the acquisition of PetMedix Ltd, a privately held research and development stage animal health biopharmaceutical company based in the U.K., which develops antibody-based therapeutics for companion animals.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kcapexIncreaseGet every 10-K signal for Zoetis and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Zoetis this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/48291686-b817-4506-b5fd-93e1ebbdf93e returns this record as JSON. POST /v1/companies/enrich returns every signal for zoetis.com.
{
"signal_id": "48291686-b817-4506-b5fd-93e1ebbdf93e",
"signal_type": "sec-10k",
"signal_subtype": "capexIncrease",
"detected_at": "2026-02-17T06:31:12.916+00:00",
"company": {
"name": "Zoetis",
"domain": "zoetis.com"
},
"data": {
"detail": "The acquisitions of PetMedix (U.K.) and adivo GmbH (Germany) represent a strategic capital allocation to enhance R&D capabilities, specifically in antibody-based therapies. These deals create integration needs and signal a long-term investment focus on advanced biopharmaceuticals.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "Acquired two R&D biopharma companies in 2023 to bolster antibody therapeutics pipeline",
"excerpts": "In 2023, the company completed the acquisition of PetMedix Ltd, a privately held research and development stage animal health biopharmaceutical company based in the U.K., which develops antibody-based therapeutics for companion animals.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/zts-20251231.htm",
"filing_date": "2026-02-12",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Budget available",
"signal_category": "financial",
"regions_mentioned": [
"U.K.",
"Germany"
]
}
}
curl https://signals.autobound.ai/v1/signals/48291686-b817-4506-b5fd-93e1ebbdf93e \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"zoetis.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.